Literature DB >> 12668787

Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD.

K Vonbank1, R Ziesche, T W Higenbottam, L Stiebellehner, V Petkov, P Schenk, P Germann, L H Block.   

Abstract

BACKGROUND: Pulmonary hypertension is a frequent complication of severe chronic obstructive pulmonary disease (COPD) and a major cause of morbidity and mortality in this condition. Based on the improved survival of these patients due to long term oxygen therapy and the potent and selective pulmonary vasodilation by inhaled nitric oxide, the safety and effectiveness of the combined inhalation of these two gases over a 3 month period was assessed.
METHODS: Forty patients with secondary pulmonary hypertension due to COPD were randomly assigned to receive either oxygen alone or "pulsed" inhalation of nitric oxide with oxygen over a period of 3 months. "Pulsed" inhalation of nitric oxide was used to reduce pulmonary ventilation-perfusion mismatch and formation of toxic reaction products of nitric oxide and oxygen.
RESULTS: Compared with oxygen alone, the combined inhalation of nitric oxide and oxygen caused a significant decrease in mean (SE) pulmonary artery pressure (from 27.6 (4.4) mm Hg to 20.6 (4.9) mm Hg, p<0.001) and pulmonary vascular resistance index (from 569.7 (208.1) to 351.3 (159.9) dyne x s(-1) x cm(-5) x m(-2), p<0.001) without decreasing arterial oxygenation. Cardiac output increased by 0.5 litres (from 5.6 (1.3) l/min to 6.1 (1.0) l/min, p=0.025). Systemic haemodynamics and left heart function remained unchanged during this period and no increase in toxic reaction products of nitric oxide was observed.
CONCLUSIONS: This is the first controlled trial indicating that the "pulsed" inhalation of nitric oxide together with oxygen may be safely and effectively used for the long term treatment of severe COPD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668787      PMCID: PMC1746623          DOI: 10.1136/thorax.58.4.289

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  29 in total

1.  Ensuring safe and effective medical devices.

Authors:  David W Feigal; Susan N Gardner; Mark McClellan
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

2.  Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension.

Authors:  J Pepke-Zaba; T W Higenbottam; A T Dinh-Xuan; D Stone; J Wallwork
Journal:  Lancet       Date:  1991-11-09       Impact factor: 79.321

Review 3.  Autoxidation kinetics of aqueous nitric oxide.

Authors:  P C Ford; D A Wink; D M Stanbury
Journal:  FEBS Lett       Date:  1993-07-12       Impact factor: 4.124

4.  Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease.

Authors:  A T Dinh-Xuan; T W Higenbottam; C A Clelland; J Pepke-Zaba; G Cremona; A Y Butt; S R Large; F C Wells; J Wallwork
Journal:  N Engl J Med       Date:  1991-05-30       Impact factor: 91.245

5.  Hemodynamic effect of hydralazine in advanced, stable chronic obstructive pulmonary disease with cor pulmonale. Immediate and short-term evaluation at rest and during exercise.

Authors:  E Lupi-Herrera; M Seoane; J Verdejo
Journal:  Chest       Date:  1984-02       Impact factor: 9.410

Review 6.  Medical treatment of pulmonary hypertension in chronic lung disease.

Authors:  E Weitzenblum; R Kessler; M Oswald; P Fraisse
Journal:  Eur Respir J       Date:  1994-01       Impact factor: 16.671

7.  Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease.

Authors:  C Melot; R Hallemans; R Naeije; P Mols; P Lejeune
Journal:  Am Rev Respir Dis       Date:  1984-10

8.  Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease.

Authors:  E Weitzenblum; A Sautegeau; M Ehrhart; M Mammosser; A Pelletier
Journal:  Am Rev Respir Dis       Date:  1985-04

9.  Pseudomonas aeruginosa and Serratia marcescens contamination associated with a manufacturing defect in bronchoscopes.

Authors:  David L Kirschke; Timothy F Jones; Allen S Craig; Patricia S Chu; Glenda G Mayernick; Jayesh A Patel; William Schaffner
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  Effects of dipyridamole on the hypoxemic pulmonary hypertension of patients with chronic obstructive pulmonary disease.

Authors:  G G Nenci; M Berrettini; T Todisco; V Costantini; P Parise
Journal:  Respiration       Date:  1988       Impact factor: 3.580

View more
  33 in total

1.  Inhaled nitric oxide therapy in adults: European expert recommendations.

Authors:  Peter Germann; Antonio Braschi; Giorgio Della Rocca; Anh Tuan Dinh-Xuan; Konrad Falke; Claes Frostell; Lars E Gustafsson; Philippe Hervé; Philippe Jolliet; Udo Kaisers; Hector Litvan; Duncan J Macrae; Marco Maggiorini; Nandor Marczin; Bernd Mueller; Didier Payen; Marco Ranucci; Dietmar Schranz; Rainer Zimmermann; Roman Ullrich
Journal:  Intensive Care Med       Date:  2005-06-23       Impact factor: 17.440

Review 2.  Inhaled pulmonary vasodilators: a narrative review.

Authors:  Kai Liu; Huan Wang; Shen-Ji Yu; Guo-Wei Tu; Zhe Luo
Journal:  Ann Transl Med       Date:  2021-04

Review 3.  Pulmonary hypertension in chronic obstructive pulmonary disease and emphysema patients: prevalence, therapeutic options and pulmonary circulatory effects of lung volume reduction surgery.

Authors:  Isabelle Opitz; Silvia Ulrich
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

4.  Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications.

Authors:  Raúl San José Estépar; Gregory L Kinney; Jennifer L Black-Shinn; Russell P Bowler; Gordon L Kindlmann; James C Ross; Ron Kikinis; Meilan K Han; Carolyn E Come; Alejandro A Diaz; Michael H Cho; Craig P Hersh; Joyce D Schroeder; John J Reilly; David A Lynch; James D Crapo; J Michael Wells; Mark T Dransfield; John E Hokanson; George R Washko
Journal:  Am J Respir Crit Care Med       Date:  2013-07-15       Impact factor: 21.405

5.  Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial.

Authors:  David J Lederer; Matthew N Bartels; Neil W Schluger; Frances Brogan; Patricia Jellen; Byron M Thomashow; Steven M Kawut
Journal:  COPD       Date:  2012-02-23       Impact factor: 2.409

6.  Pulmonary arterial remodeling in chronic obstructive pulmonary disease is lobe dependent.

Authors:  Jeremy P Wrobel; Catriona A McLean; Bruce R Thompson; Christopher R Stuart-Andrews; Eldho Paul; Gregory I Snell; Trevor J Williams
Journal:  Pulm Circ       Date:  2013-12-11       Impact factor: 3.017

Review 7.  Cardiac disease in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Steven Kadiev; Gerard J Criner; Steven M Scharf; Omar A Minai; Philip Diaz
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 8.  Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management.

Authors:  Joan Albert Barberà; Isabel Blanco
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

Review 9.  Pulmonary hypertension and chronic cor pulmonale in COPD.

Authors:  Adil Shujaat; Ruth Minkin; Edward Eden
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

Review 10.  Update on pulmonary hypertension complicating chronic obstructive pulmonary disease.

Authors:  Soma Jyothula; Zeenat Safdar
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.